Impact of cetuximab in current treatment of metastatic colorectal cancer.
作者： Miguel Jhonatan Sotelo Lezama , Javier Sastre Valera , Eduardo Díaz-Rubio García
DOI: 10.1517/14712598.2014.883376
关键词: Neuroblastoma 、 Oncology 、 Colorectal cancer 、 Disease 、 Oncogene 、 Clinical trial 、 Internal medicine 、 KRAS 、 Cetuximab 、 Viral Oncogene 、 Medicine
摘要: Introduction: Cetuximab is a chimeric monoclonal antibody targeting the EGFR, which has proven effective in patients with metastatic colorectal cancer (mCRC), wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS). Areas covered: The aim of this manuscript to discuss current impact cetuximab most important scenarios mCRC. We review currently available data regarding role other biomarkers, such as mutational status neuroblastoma RAS (v-ras) identifying who could benefit from anti-EGFR. In addition, included relevant clinical trials that have assessed effectiveness management potentially resectable disease and first-line treatment KRAS mCRC, well anti-EGFR agent on patient quality life. Expert opinion: had progressive development earliest later stages evolu...
sci-hub.se 参考文章(114)
Hideo Masui, Ian Altas, John Mendelsohn, Zhen Fan, Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Research. ,vol. 53, pp. 4322- 4328 ,(1993)
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Juergen Lerchenmueller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Joerg Hielscher, Michael Scholz, Sebastian Mueller, Britta Schaefer, Dominik Paul Modest, Andreas Jung, Sebastian Stintzing, Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.LBA3506
Janghee Woo, Neil Palmisiano, William Tester, John C. Leighton, Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer. ,vol. 119, pp. 1941- 1950 ,(2013) , 10.1002/CNCR.27994
S. Stintzing, J. Neumann, A. Jung, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jaeger, T. Heintges, C. Stoll, D. P. Modest, T. Kirchner, W. Scheithauer, V. Heinemann, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. Journal of Clinical Oncology. ,vol. 29, pp. 3575- 3575 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.3575
John Neil Primrose, Stephen Falk, Meg Finch-Jones, Juan W Valle, David Sherlock, Joanne Hornbuckle, James Gardner-Thorpe, David Smith, Charles Imber, Tamas Hickish, Brian Davidson, David Cunningham, Graeme John Poston, Tim Maughan, Myrrdyn Rees, Louise Stanton, Louisa Little, Megan Bowers, Wendy Wood, John A Bridgewater, None, A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. Journal of Clinical Oncology. ,vol. 31, pp. 3504- 3504 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.3504
Paul Perrotte, Hiroki Kuniyasu, Beryl Y. Eve, Daniel J. Hicklin, Keiji Inoue, Colin P. N. Dinney, Robert Radinsky, Takashi Matsumoto, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research. ,vol. 5, pp. 257- 265 ,(1999)
J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, S Ogino, S Hooshmand, E Kwak, E Freed, J A Meyerhardt, Z Saridaki, V Georgoulias, D Finkelstein, C S Fuchs, M H Kulke, R A Shivdasani, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer. ,vol. 101, pp. 465- 472 ,(2009) , 10.1038/SJ.BJC.6605164
Dominik P. Modest, Ruediger P. Laubender, Sebastian Stintzing, Clemens Giessen, Christoph Schulz, Michael Haas, Ulrich Mansmann, Volker Heinemann, Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncologica. ,vol. 52, pp. 956- 962 ,(2013) , 10.3109/0284186X.2012.752580
Loredana Vecchione, Bart Jacobs, Nicola Normanno, Fortunato Ciardiello, Sabine Tejpar, EGFR-targeted therapy Experimental Cell Research. ,vol. 317, pp. 2765- 2771 ,(2011) , 10.1016/J.YEXCR.2011.08.021
Inti Zlobec, Michal Kovac, Priska Erzberger, Francesca Molinari, Michel P. Bihl, Alexander Rufle, Anja Foerster, Milo Frattini, Luigi Terracciano, Karl Heinimann, Alessandro Lugli, Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. International Journal of Cancer. ,vol. 127, pp. 2569- 2575 ,(2010) , 10.1002/IJC.25265